CN Patent

CN115197203B — 苯胺嘧啶类化合物、其制备方法及应用

Assigned to Shanghai Institute of Pharmaceutical Industry · Expires 2024-06-25 · 2y expired

What this patent protects

本发明公开了一种苯胺嘧啶类化合物、其制备方法及应用。本发明具体公开了一种如式I所示的苯胺嘧啶类化合物或其药学上可接受的盐，并公开了其制备方法及其在制备用于治疗癌症的药物中的应用。本发明的苯胺嘧啶类化合物不仅能够抑制EGFR L858R/T790M二突变，对EGFR L858R/T790M/C797S三突变也有良好的抑制作用。

USPTO Abstract

本发明公开了一种苯胺嘧啶类化合物、其制备方法及应用。本发明具体公开了一种如式I所示的苯胺嘧啶类化合物或其药学上可接受的盐，并公开了其制备方法及其在制备用于治疗癌症的药物中的应用。本发明的苯胺嘧啶类化合物不仅能够抑制EGFR L858R/T790M二突变，对EGFR L858R/T790M/C797S三突变也有良好的抑制作用。

Drugs covered by this patent

mobocertinib-succinate (MOBOCERTINIB SUCCINATE)

Patent Metadata

Patent number: CN115197203B
Jurisdiction: CN
Classification: —
Expires: 2024-06-25
Drug substance claim: No
Drug product claim: No
Assignee: Shanghai Institute of Pharmaceutical Industry
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.